Navigation Links
China Yongxin Pharmaceuticals, Inc. Announces Results for the Third Quarter Ended September 30, 2009

CHANGCHUN, China and LOS ANGELES, Dec. 10 /PRNewswire-Asia-FirstCall/ -- China Yongxin Pharmaceuticals, Inc. (OTC Bulletin Board: CYXN) ("Yongxin" or "the Company"), a leading pharmaceutical distributor and chain drugstore operator, today announced financial results for the third quarter ended September 30, 2009.

"While we recognize that many of our products depend on discretionary spending, we expect as the economy continues to recover and consumer confidence picks up further, sales will gain momentum in 2010 and beyond. In the third quarter, we maintained our sales activities and saw improved gross margin as the Company's shift to higher margin products in its retail segment contributed to a more profitable mix of business. Management believes that overall gross profit will continue to improve for the remainder of 2009 and into next year," commented Mr. Yongxin Liu, Chairman and Chief Executive Officer of Yongxin.

"Further, we have initiated distribution of essential drugs and believe the government's new efforts on centralized distribution and the broader healthcare reform provide a myriad of growth opportunities. As one of the leading drug distributors in Northeastern China, we are well positioned to capitalize on these developments and build sustainable and long-term shareholder value," concluded Mr. Liu.

Highlights for the three months Ended September 30, 2009

Net revenue totaled approximately $10.8 million for the three months ended September 30, 2009, a decline of 29.8% from $15.5 million for the same period of 2008, due to lower sales from the Company's wholesale business as result of a change in its sales strategy. In the third quarter, Yongxin shifted its focus to the retail sector as the benefits from China's proposed National Medical Policy for the Company's wholesale business segment have taken longer than initially anticipated.

Cost of goods sold for the third quarter of 2009 decreased to $12.4 million, or 70.9% of net revenue, from $7.7 million, or 80.3% in the 2008 third quarter, largely in line with sales decline.

Gross profit for the three months ended September 30, 2009 totaled $3.1 million, or 29.1% of net sales, compared with gross profit of $3.0 million, or 19.7% of net sales, for the same period of 2008. The improvement in gross margin was mainly due to a better sales mix and a focus on higher margin products, including cosmetics and certain health and organic products.

Operating expenses totaled approximately $3.3 million for the third quarter of 2009, up 168.7% from $1.2 million in the third quarter of 2008. As a percentage of net revenue, third-quarter 2009 total operating expenses amounted to 30.4%, compared to third-quarter 2008 operating expenses at 7.9% of net revenue. This was largely attributable to a sharp increase in general and administrative expenses, which more than quintupled in the third quarter, primarily driven by allowance for doubtful accounts for accounts receivable and accrued litigation fees. Selling expenses rose moderately by 6.3% as the Company opened two new retail stores during the third quarter.

Other income amounted to $1.1 million for the three months ended September 30, 2009, an increase of 85.5% from $0.5 million for the same period in 2008, largely due to higher sponsorship and rebates from customers and suppliers in combination with an 87.6% decline in interest expenses.

The Company's net income attributable to common shares during the three months ended September 30, 2009 was $0.5 million down 71.5% from $1.7 million for the three months ended September 30, 2008. In addition to higher operating expenses, third-quarter net income was also negatively affected by a change in the collection of sponsorship fees and rebates from customers and suppliers from an annual basis to a quarterly basis.

The earnings per basic and diluted share were $0.01 for the three months ended September 30, 2009, down from $0.05 for the three months ended September 30, 2008.

Nine Months Results Ended September 30, 2009

Total revenue for the first nine months of 2009 was approximately $29.2 million, down 35.1% from the first nine months of 2008. Gross profit for the first nine months of 2009 was $8.0 million, a decrease of 3.7% from gross profit of $8.4 million in the comparable period a year ago. Gross margin was 27.8% for the first nine months of 2009, up from 18.7% for the same period in 2008. The Company recorded an operating income of $1.7 million, compared with operating income of $4.4 million in the first nine months of 2008. Net income attributable to common shares for the first nine months of 2009 was $1.9 million, compared with $3.1 million in the first nine months of 2008. Basic and diluted earnings per share were $0.06 for the first nine months of 2009 compared to 0.10 in the first nine months of 2008.

Financial Condition

As of September 30, 2009, Yongxin had 1.4 million in cash and cash equivalents, and approximately $12.1 million in working capital. As of September 30, 2009, shareholders' equity was $20.5 million. For the first nine months of 2009, the Company generated $2.6 million in cash from operations versus $3.7 million for the same period in 2008.

Recent Events

Yongxin announced on November 30 that it has completed preparation for distribution of medicines on the Essential Drug List, which was recently formalized by the Chinese government. Drugs on the National Essential Drugs List will be purchased and distributed to medical facilities including hospitals, clinics, pharmacies, etc. All drugs on the List will be covered by the basic insurance plan supported by the government. The government will invite public bidding for centralized distribution for essential drugs. Currently, Yongxin distributes 297 products out of 307 drugs listed on EDL. As one of the top medicine distributors in Jilin province with modern pharmaceutical logistic center, China Yongxin launched corresponding business preparation for public bidding and distribution for the first batch of 138 township hospitals and 11 city hospitals in Jilin province. The official public bidding is expected to be announced before the end of 2009. The winning of first batch will increase revenues of drug distribution and will help facilitate winning other batches of hospitals.

About China Yongxin Pharmaceuticals, Inc.

China Yongxin Pharmaceuticals, Inc. was founded in 1993 as the Changchun Yongxin Dirui Medical Co., Ltd. (Yongxin), a wholesale drug distributor. Its products include Chinese traditional medicines, pharmaceutical preparations, natural health products, health food, cosmetics, and medical equipment. It began retail operations in 2004, and in 2005, it gained franchise rights from one of the world's largest drug chains for China's Jilin Province. By the end of 2007, the Company had become one of the fastest growing pharmaceutical companies in China through its retail chain of 93 drug outlets as well as wholesale distribution and manufacturing operations in Northeastern China. For more information about China Yongxin Pharmaceuticals, please visit .

Forward-Looking Statements

This news release contains certain "forward-looking statements." Forward- looking statements are based on current expectations and assumptions and are inherently subject to risks and uncertainties, some of which cannot be predicted or quantified, and many of which are beyond the Company's control. The forward-looking statements are also identified through the use of words "believe," enable," "may," "will," "could," "intends," "estimate," "anticipate," "plan," "predict" "probable," "potential," "possible," "should," "continue," and other words of similar meaning. Actual results could differ materially from these forward-looking statements as a result of a number of risk factors detailed in the Company's periodic reports filed with the SEC. Given these risks and uncertainties, investors are cautioned not to place undue reliance on such forward-looking statements and no assurances can be given that such statements will be achieved. China Yongxin Pharmaceutical Inc. does not assume any duty to publicly update or revise the material contained herein.

                           CONSOLIDATED BALANCE SHEETS
                  AS OF SEPTEMBER 30, 2009 AND DECEMBER 31, 2008

                                                  September 30, December 31,
                                                       2009         2008
    Current Assets:
    Cash and cash equivalents                       $1,371,842     $609,422
    Accounts receivable, net                         6,622,395    6,030,874
    Notes receivable                                 3,074,753    1,334,078
    Other receivable, net                            2,823,356      356,573
    Advances to suppliers                            6,576,641    6,186,269
    Prepaid expenses                                        --      345,686
    Inventory, net                                   8,747,431    7,864,677
    Total Current Assets                            29,216,418   22,727,579

    Property and Equipment, net                      8,733,094    2,680,207

    Construction In Progress                           913,054    6,066,249

    Intangible Assets, net                              47,324       73,687
    Total Assets                                   $38,909,890  $31,547,722


    Current Liabilities:
    Accounts payable                                $4,923,000   $3,255,148
    Accrued expenses & other payable                 4,496,232    2,412,067
    Advances from customers                          2,901,552    2,580,894
    Tax payable                                      2,183,714    1,240,411
    Loans to related parties                           184,662      184,662
    Short-term loans payable                         1,439,578    1,967,185
    Deferred income                                    305,340      273,753
    Shares to be issued                                 47,000       35,000
    Net liabilities of discontinued operations         628,837      628,837
    Total Current Liabilities                       17,109,915   12,577,957

    Long term loan                                   1,320,300    1,320,390

    Commitments and Contingency                             --           --

    Stockholders' Equity:
    Preferred stock, $0.001 par value;
     5,000,000 shares authorized; 5,000,000
     shares issued and outstanding                       5,000        5,000
    Common stock; $0.001 par value; 75,000,000
     shares authorized; 32,110,540 shares issued
     and outstanding as of September 30, 2009
     and 31,400,540 shares issued and outstanding
     as of December 31, 2008                            32,111       31,401
    Additional paid in capital                         719,536      615,906
    Deferred consulting expense - issuance of
     warrants                                          (11,850)     (72,815)
    Prepaid consulting - issuance of shares            (12,500)     (68,750)
    Receivable from a related party                    (50,000)     (50,000)
    Statutory reserve                                2,170,805    1,841,241
    Other comprehensive income                       1,685,247    1,684,649
    Retained earnings                               11,171,145    9,563,803
    Non-controlling interest                         4,770,180    4,098,940
     Total Stockholders' Equity                     20,479,675   17,649,375
    Total Liabilities and Stockholders' Equity     $38,909,890  $31,547,722

                            SEPTEMBER 30, 2009 AND 2008

                              For the Three-Month       For the Nine-Month
                                 Periods Ended             Periods Ended
                                 September 30,             September 30,
                               2009         2008         2009         2008
    Net Revenues           $10,844,786  $15,451,100  $29,199,325  $45,025,197
    Cost of Goods Sold      (7,685,369) (12,412,576) (21,090,595) (36,602,807)
    Gross profit             3,159,417    3,038,524    8,108,730    8,422,390

    Operating Expenses:
    Selling expenses           912,094      858,038    2,495,546    2,582,411
    General and
     expenses                2,386,349      369,471    3,908,223    1,482,786
    Total operating
     Expenses                3,298,443    1,227,509    6,403,769    4,065,197

    Income (Loss) From
     Operations               (139,026)   1,811,015    1,704,961    4,357,193

    Other Income (Expense):
    Other income             1,112,309      683,618    1,906,864    1,517,758
    Other expense              (19,981)     (42,745)     (40,763)     (77,651)
    Interest income
     (expense)                  (6,919)     (55,845)       1,066     (282,957)
    Total other income       1,085,409      585,028    1,867,166    1,157,150

    Operating Income Before
     Income Tax and Non
     controlling Interest      946,383    2,396,043    3,572,127    5,514,343

    Provision for income tax  (233,908)    (547,088)    (964,474)  (1,487,230)

    Net Income Before Non
     controlling Interest      712,475    1,848,955    2,607,653    4,027,113

    Non controlling interest  (240,362)    (191,894)    (670,747)    (883,775)

    Net Income                 472,113    1,657,061    1,936,906    3,143,338

    Other Comprehensive
    Foreign exchange
     translation gain           18,938       26,258          598      862,970

    Net Comprehensive Income   491,051    1,683,319    1,937,504   $4,006,308

    Earning per share
    Basic                        $0.01        $0.05        $0.06        $0.10
    Diluted                      $0.01        $0.05        $0.06        $0.10
    Weighted average number
     of  shares outstanding
    Basic                   31,667,062   31,291,845   31,288,904   31,150,819
    Diluted                 32,125,923   31,291,845   31,747,765   31,150,819

SOURCE China Yongxin Pharmaceuticals, Inc.

SOURCE China Yongxin Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related medicine technology :

1. HUYA Bioscience Intl Announces Clinical Trial Milestones in China for Promising New Anti-Arrhythmic Compound; Data Supports Desirable Safety Profile
2. HUYA Bioscience Intl Announces World-Class Clinical Advisory Team for New Anti-Arrhythmic Compound Sourced From China
3. HUYA Bioscience Intl Announces First Pre-IND Outcome for a Development Stage Compound Sourced From China - HBI-8000, Promising New Cancer Compound
4. HUYA Bioscience Intl Announces Pre-IND Outcome for HBI-3000 - Promising Anti-Arrhythmia Compound Sourced From China
5. China Sky One Medical, Inc. Announces 26 New Drugs in Clinical Trials
6. RHEI Pharmaceuticals Announces the Initiation of the Final Clinical Study for Approval of Tibozole in China
7. Varian Medical Systems to Exhibit Cancer Treatment and X-ray Imaging Technologies at China Med Exhibition
8. China Sky One Medical, Inc. Achieves Significant Breakthrough in Research for Sudden Cardiac Death (SCD) Early Examination Kit
9. China Animal Welfare Law Under Review While 36,000 Dogs Culled
10. China-Biotics, Inc. Prices $69 Million Public Offering of Common Stock
11. Clifford Chance Advises Pfizer on Conditional Clearance in China of Its Merger with Wyeth
Post Your Comments:
(Date:10/2/2017)... , Oct. 2, 2017  Eli Lilly and Company ... results for the third quarter of 2017 on Tuesday, ... call on that day with the investment community and ... The conference call will begin at 9 a.m. ... access a live webcast of the conference call through ...
(Date:10/2/2017)... 2, 2017 Halo Labs announces the European launch of ... the HORIZON at MIBio 2017 in Cambridge, U.K ... particulate matter in biopharmaceutical samples with unprecedented speed and sensitivity while ... technique Backgrounded Membrane Imaging. ... HORIZON subvisible particle analysis system ...
(Date:9/28/2017)... Hill-Rom Holdings, Inc. (NYSE: HRC), will host ... webcast on Friday, November 3, 2017, beginning at 7:00 ... approximately 8:30 a.m. (CDT) / 9:30 a.m. (EDT). ... performance and guidance for 2018, Hill-Rom executives will also ... performance, and long-range financial outlook through 2020. ...
Breaking Medicine Technology:
(Date:10/13/2017)... ... October 13, 2017 , ... Many families have long-term insurance that covers ... companies have a waiver for care if the client has a cognitive impairment diagnosis. ... pays for care, is often waived, so the benefits from their insurance start immediately,” ...
(Date:10/13/2017)... ... October 13, 2017 , ... Talented host, actor ... on sciatica in a new episode of "Success Files," which is an award-winning ... innovation and investigates each subject in-depth with passion and integrity. , Sciatica occurs ...
(Date:10/12/2017)... , ... October 12, 2017 , ... ... now treating sleep apnea using cutting-edge Oventus O2Vent technology. As many ... sleep disorder characterized by frequent cessation in breathing. Oral appliances can offer significant ...
(Date:10/12/2017)... (PRWEB) , ... October 12, 2017 , ... ... AccentCare, a leader in post-acute health care, have expanded their existing home health ... Home Health. , AccentCare has been operating a joint venture home health company ...
(Date:10/12/2017)... ... October 12, 2017 , ... On Saturday, October 21, the Health & ... by Moonlight to raise money for the American Heart Association Heart Walk. Teams of ... will work together to keep their treadmills moving for 5 hours. Treadmills will start ...
Breaking Medicine News(10 mins):